semaglutide and cirrhosis fatty liver 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial Semaglutide Shows Major Promise for – Semaglutide Showing Promise in Treating

May slow down progression of joint diseases such as osteoarthritis and rheumatoid arthritis, because of anti-inflammatory effect and weight loss

The study was funded by Novo Nordisk, which designed and oversaw the trial

In May 2024, the Danish Medicines Agency announced new regulations requiring doctors to prescribe cheaper alternative medications to patients with type 2 diabetes before considering GLP-1 drugs (like Novo Nordisks Ozempic, effective from the 25 th of November, 2024) in an effort to manage soaring demand and public spending on these medications (Christensen 2024)

If you have questions about your specific targets, bring them to your next check-in.

Third, obesity has a strong correlation with depression, and people with obesity may be more often prescribed GLP-1RAs